HRPC(SH:600829)2025-04-18 09:00Financial Performance - The company's operating revenue for Q1 2025 was CNY 2,666,810,119.69, an increase of 2.65% compared to CNY 2,598,035,321.93 in the same period last year[4] - Net profit attributable to shareholders decreased by 41.48% to CNY 45,840,864.76 from CNY 78,333,942.38 year-on-year[4] - The basic earnings per share fell by 41.45% to CNY 0.0791 from CNY 0.1351 in the previous year[4] - The operating profit for Q1 2025 was RMB 60,682,040.14, a decrease of 41% compared to RMB 102,880,789.51 in Q1 2024[20] - The net profit for Q1 2025 was CNY 45,840,887.15, a decrease of 41.5% compared to CNY 78,333,942.38 in Q1 2024[21] - The basic and diluted earnings per share for Q1 2025 were CNY 0.0791, down from CNY 0.1351 in Q1 2024, representing a decline of 41.5%[21] - The company's revenue for Q1 2025 was 782,857.14 RMB, a decrease of 39.2% compared to 1,287,954.56 RMB in Q1 2024[29] - Operating profit for Q1 2025 was 26,796.39 RMB, down from 580,778.56 RMB in Q1 2024, indicating a significant decline in profitability[29] - Net profit for Q1 2025 was 20,100.11 RMB, compared to 580,778.56 RMB in Q1 2024, reflecting a decrease of approximately 96.5%[30] Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,198,652,143.92, reflecting a slight increase of 0.45% from CNY 7,166,181,171.04 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to RMB 7,198,652,143.92, compared to RMB 7,166,181,171.04 at the end of 2024[16] - Total liabilities decreased to RMB 4,271,667,512.60 as of March 31, 2025, from RMB 4,285,037,426.87 at the end of 2024[16] - The total current assets amounted to CNY 690,736,664.29 as of March 31, 2025, compared to CNY 691,028,886.44 at the end of 2024[26] - Total liabilities as of the end of the reporting period were 57,750,282.81 RMB, slightly down from 58,188,357.11 RMB in the previous period[28] Cash Flow - The company experienced a net cash flow from operating activities of -CNY 302,722,327.06, an improvement from -CNY 336,296,768.32 in the previous year[4] - The net cash flow from operating activities for Q1 2025 was -CNY 302,722,327.06, an improvement from -CNY 336,296,768.32 in Q1 2024[23] - The net cash flow from operating activities for Q1 2025 was 214,715.31 RMB, a recovery from a negative cash flow of -604,123.19 RMB in Q1 2024[33] - The company reported a decrease in cash flow from investing activities, with a net cash outflow of -CNY 626,498.89 in Q1 2025 compared to -CNY 1,131,156.33 in Q1 2024[24] - The company’s cash flow from financing activities generated a net inflow of CNY 28,014,768.39 in Q1 2025, down from CNY 130,771,358.30 in Q1 2024[24] Shareholder Information - The company reported a total of 28,753 ordinary shareholders at the end of the reporting period[9] Business Operations - The increase in accounts receivable led to a rise in bad debt provisions, contributing to the decline in net profit[4] - The wholesale business faced margin pressure due to policy impacts, affecting overall profitability[4] - The company plans to enhance its DTP business and improve professional pharmaceutical service capabilities to drive retail sales growth[5] - Accounts receivable increased to RMB 4,513,327,199.29 as of March 31, 2025, compared to RMB 4,054,299,495.65 at the end of 2024, indicating a growth of 11.3%[14] - Inventory as of March 31, 2025, was RMB 1,047,211,139.70, a slight decrease from RMB 1,100,790,454.55 at the end of 2024[14] Legal Matters - The company is currently undergoing a major litigation process, with the outcome uncertain, which may impact future profits[12] Financial Position - The cash and cash equivalents as of March 31, 2025, were RMB 745,669,392.99, down from RMB 1,099,832,339.51 as of December 31, 2024[14] - The equity attributable to shareholders increased to RMB 2,927,027,389.95 as of March 31, 2025, compared to RMB 2,881,186,525.19 at the end of 2024[16] - The total equity of the company was reported at 1,601,675,157.48 RMB, showing a marginal increase from 1,601,655,057.37 RMB[28] - Cash and cash equivalents at the end of Q1 2025 were 11,488,646.57 RMB, up from 2,452,554.78 RMB at the end of Q1 2024[33] Management Expenses - The company reported a decrease in management expenses to 637,167.20 RMB in Q1 2025 from 558,744.04 RMB in Q1 2024[29] - The company received 994,000.00 RMB from sales in Q1 2025, significantly higher than 300,000.00 RMB in Q1 2024[32] - The company reported a financial income of -6,423.61 RMB in Q1 2025, compared to -1,205.81 RMB in Q1 2024, indicating an increase in financial costs[29]